Director, Program Management

Waltham, Massachusetts, United States

Auto‑apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates should possess a Bachelor's degree in a related field, such as Business Administration, Project Management, or a scientific discipline, and ideally have 8+ years of experience in program management, particularly within the pharmaceutical or biotechnology industry. Strong leadership, communication, and stakeholder management skills are essential, along with a demonstrated ability to manage complex projects and drive results. Experience with cross-functional teams and matrix organizations is highly desirable.

Responsibilities

The Director, Program Management will lead the operations of one or more cross-functional teams, focusing on priorities, goal achievement, and resource allocation, while fostering a collaborative and sustainable team environment. They will partner closely with the Program Team Leader and subject matter experts to ensure comprehensive program plans are developed and executed effectively, incorporating agile methodologies to adapt to emerging data. The role involves facilitating discussions, eliciting recommendations, and managing stakeholders at all levels of the company, with a focus on achieving strategic development goals and maintaining a patient-focused approach.

Skills

Program Management

Cross-functional Collaboration

Project Planning

Risk Management

Agile Methodology

Stakeholder Engagement

Decision-Making

Data-Driven Adaptability

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Watertown, MassachusettsHeadquarters

2018Year Founded

$106MTotal Funding

SERIES_ACompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.

Manufacturing bottlenecks could hinder scaling of Dyno's operations.

Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.

Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.

Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.

Collaboration with NVIDIA enhances biological sequence design for gene therapies.

Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI

Try Jobo Free